We are now entering a new era of RNA therapies, such that mRNA-based vaccines and RNA interference approaches such as siRNA have already been launched on the pharmaceutical market. However, there are no FDAapproved RNA-based therapeutics for cancer treatment. Among RNA molecules, miRNAs represent a promising solution against cancer. Despite the ability to target multiple pathways, miRNA-based therapeutics struggle to reach phase 3 clinical trial. A reason of this delay is linked to complications of selective administration of miRNAs to their target, the tumor cell. Because of this, an efficient delivery system is necessary. In this sense, exosomes are considered the most promising miRNA-based therapeutic carriers in terms of safety and efficient cargo delivery. Furthermore, researchers have developed a new strategy to overcome the tumor capacity by using exosomes to release unnecessary miRNAs, shedding light on a new generation therapy of cancer treatment. The review describes recent advances in the application of miRNAs in the treatment of cancer, the use of exosomes for miRNA delivery, focusing on new approaches to overcome the limits of miRNA-loaded exosomes in clinical applications.
Advances in RNA cancer therapeutics: New insight into exosomes as miRNA delivery / Volpini, Luca; Monaco, Federica; Santarelli, Lory; Neuzil, Jiri; Tomasetti, Marco. - In: ASPECTS OF MOLECULAR MEDICINE. - ISSN 2949-6888. - 1:(2023), p. 100005. [10.1016/j.amolm.2023.100005]
Advances in RNA cancer therapeutics: New insight into exosomes as miRNA delivery
Luca Volpini;Federica MonacoSecondo
;Lory Santarelli;Marco Tomasetti
2023-01-01
Abstract
We are now entering a new era of RNA therapies, such that mRNA-based vaccines and RNA interference approaches such as siRNA have already been launched on the pharmaceutical market. However, there are no FDAapproved RNA-based therapeutics for cancer treatment. Among RNA molecules, miRNAs represent a promising solution against cancer. Despite the ability to target multiple pathways, miRNA-based therapeutics struggle to reach phase 3 clinical trial. A reason of this delay is linked to complications of selective administration of miRNAs to their target, the tumor cell. Because of this, an efficient delivery system is necessary. In this sense, exosomes are considered the most promising miRNA-based therapeutic carriers in terms of safety and efficient cargo delivery. Furthermore, researchers have developed a new strategy to overcome the tumor capacity by using exosomes to release unnecessary miRNAs, shedding light on a new generation therapy of cancer treatment. The review describes recent advances in the application of miRNAs in the treatment of cancer, the use of exosomes for miRNA delivery, focusing on new approaches to overcome the limits of miRNA-loaded exosomes in clinical applications.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.